| Overview |
| bsm-60298r-hrp-100ul |
| CD134 Recombinant Antibody, HRP Conjugated |
| WB, IHC-P, IHC-F |
| Human |
| Specifications |
| HRP |
| Rabbit |
| KLH conjugated synthetic peptide derived from human CD134 |
| Recombinant |
| IgG |
| Lot dependent |
| Purified by Protein A. |
| Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target |
| 7293 |
| P43489 |
| Cell membrane |
| CD134 / OX40L receptor; Tumor necrosis factor receptor superfamily member 4; TNFRSF4; ACT 35; ACT35; ACT35 antigen; CD 134; CD134 antigen; Lymphoid activation antigene ACT35; OX 40; OX40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally activated glycoprotein 1 receptor; TNFRSF 4; TNR4_HUMAN. |
| The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that this receptor promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. The knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell proliferation and differentiation. [provided by RefSeq, Jul 2008]. |
| Application Dilution |
| WB |
IHC-P1:200-500 |
| IHC-P |
1:200-400 |
| IHC-F |
1:100-500 |
Powered by Bioz